PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Co-beneldopa - Parkinson's disease

PAD Profile : Co-beneldopa - Parkinson's disease

Keywords :
PD, levodopa, dopamine
Brand Names Include :
Madopar

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
  • Levodopa is recommended as a first-line treatment in the early stages of Parkinson's disease where motor symptoms are impacting on quality of life.
  • Levodopa may also be a treatment choice in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
  • Levodopa may be considered in the treatment of nocturnal akinesia in Parkinson's disease.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.

Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More